PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.58) by 53.45 percent. This is a 82 percent increase over losses of $(1.50) per share from the same period last year. The company reported quarterly sales of $33.000 thousand which missed the analyst consensus estimate of $72.000 thousand by 54.17 percent. This is a 450.00 percent increase over sales of $6.000 thousand the same period last year.